doi: 10.1016/j.freeradbiomed.2016.03.002 Lee YS, Lee C, Choung JS, Jung HS, Jun HS
It also acts upon -cells, leading to the suppression of glucagon release
This is crucial for maintaining normal cellular glucose metabolism and preventing the occurrence of related metabolic diseases
However, this complexity makes peptide synthesis more challenging and costly
Project Overview Project Code: DT-20250717-078 Project Title: An Oral Small-Molecule GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity Indications: Type 2 Diabetes (T2D), Obesity Drug Class: Small Molecule Target: Glucagon-Like Peptide-1 Receptor (GLP-1R) Development Stage: Preclinical Candidate (PCC) Key Advantages: Exceptional oral pharmacokinetic (PK) profile with high bioavailability and sustained exposure
Important Safety and Realistic Expectations Semaglutide is not FDA-approved for smoking cessation, and PlexusDx does not market compounded semaglutide as a smoking-cessation medication
